PhysChem Forum, 29 Nov 2006, Newhouse 1 Memories and the future: From experimental to in silico physical chemistry Han van de Waterbeemd AstraZeneca, DMPK.

Slides:



Advertisements
Similar presentations
1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
Advertisements

The Drug Discovery Process
1. 2 Hydrogen bonding 3 Surface tension 4 Ice, water, vapor.
Surface activity profiling: a novel physicochemical tool for the prediction of blood-brain-barrier permeation Paavo K.J. Kinnunen Helsinki Biophysics &
Advanced Medicinal Chemistry
Permeability: transporting drugs through (lipid) membranes
Recent Advances in BCS and Drug Product (BioPredictive) Dissolution
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Improving Candidate Quality Through the Prediction of Clinical Outcome.
Ionization and dissociation of drugs-1
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
234th ACS National MeetingPAPER ID: Division of Chemical Information Herman Skolnik Award Symposium Bridging the gap between discovery data and.
Jörg KeldenichNov PhysChem Forum 1 Physicochemical Properties at Bayer HealthCare (Wuppertal) and Their Use in Medicinal Chemistry.
Lipinski’s rule of five
19 March 2009KLE College of Pharmacy, Belgaum 1 Drug Design: Discovery, Development and Delivery Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor.
20/03/2008 Dept. of Pharmaceutics 1 APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY AND PROCESS RESEARCH Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate.
Solubility and Dissolution Pharmaceutical Technology.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Drug-Like Properties: Optimizing Pharmacokinetics and Safety During Drug Discovery Li Di and Edward H. Kerns ACS Short Course.
Structure-based Drug Design
Drug discovery and development
Quantitative Structure-Activity Relationships (QSAR)  Attempts to identify and quantitate physicochemical properties of a drug in relation to its biological.
Functional groups / Pharmacological Activity
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Virtual Drug Development in Southern California, A Pre-Clinical Focus in vitro tests to support IND submissions David Johnson, Ph.D. Director, DMPK MicroConstants,
ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering Universiti Malaysia Perlis.
ERT 420 BIOPHARMACEUTICAL ENGINEERING ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
David Kim Allergan Inc. SoCalBSI California State University, Los Angeles.
Using Spotfire DecisionSite to Realize the Full Value of High-Throughput Screening ADME Data Eric Milgram Pfizer Global Research & Development – La Jolla.
Atelier PK sur articles. 5 thèmes Absorption / biodisponibilité Métabolisme hépatique et effet de premier passage Les modèles in vitro d’étude de l’absorption.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
DuPont Pharmaceuticals Company Utilization of Spotfire™ in Quality Assessment & Analysis of Screening Data Thomas D.Y. Chung, Ph.D. Sr. Director, Leads.
!!!……Molecular Target Concept A gonist Antagonist.
Lipophilicity & Permeability 김연수. Chapter 5. Lipophilicity.
The Biopharmaceutical Classification System (BCS)
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Chapter 7. Solubility Chun Jong-Soo.
Chapter 6. pKa & Chapter 7. Solubility
CZ3253: Computer Aided Drug design Lecture 6: QSAR part II Prof. Chen Yu Zong Tel: Room 07-24,
김소연 Permeability OverviewPermeability FundamentalsPermeability EffectPermeability Structure Modification StrategiesProblem.
Background. For designing, discovering or developing a therapeutically relevant molecule, potency and selectivity to the target.
Part 2. Physicochemical Properties 1.Rules ( 양혜란 ) 2.Liphophilicity ( 백아름 ) 3.pKa ( 박숙진 ) 4.Solubility ( 전종수, 최영재 ) 5.Permeability ( 김소연, 강경태 )
Physiochemical properties of drugs Using the Sirius T3 to make measurements.
A truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL.
Molecular Modeling in Drug Discovery: an Overview
Physiochemical properties of drugs Some background to the Sirius T3.
Advantages of Good Drug-like Properties 손한표.
ADME Dr Basma Damiri Toxicology In general, a toxicant should be absorbed in order to have an effect. True or false? Why? False Some toxicants.
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
Page 1 Molecular Modeling Service in Profacgen. Page 2 The three-dimensional structure of a protein provides essential information about its biological.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
Drug UCIBIO Maria João Ramos
Chemistry 301 Q1 September 14, 2017: Agenda
The Biopharmaceutical Classification System (BCS)
Introduction of Biopharmaceutics & Pharmacokinetics
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Solubility and Dissolution
ADME/Tox PredictionTox Prediction. The characterization of Absorption, Distribution, Metabolism, and Excretion (also known as ADME) and Toxicity are essential.
Hanneke van der Lee, MD, PhD
About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in.
Virtual Screening.
Rules for Rapid Property Profiling from Structure
Identification & Assessment of NPS: an European Network
Properties of Water.
Properties of Water.
PREDICT.
Drug Design and Drug Discovery
Machine Learning / AI in Drug Discovery
Presentation transcript:

PhysChem Forum, 29 Nov 2006, Newhouse 1 Memories and the future: From experimental to in silico physical chemistry Han van de Waterbeemd AstraZeneca, DMPK Alderley Park, Macclesfield, UK

PhysChem Forum, 29 Nov 2006, Newhouse 2 Overview Why physchem data? Wet screening (in vitro) Web screening (in silico) Future developments

PhysChem Forum, 29 Nov 2006, Newhouse 3 Medchem evolution <1980target affinity/binding using intuition and experience >1980structure-based design >1995drug/lead filters such as rule of five >2000property-based design >2005in silico/in vitro (in combo) approaches protein crystallography attrition analyses physchem/DMPK considerations HT property screening

PhysChem Forum, 29 Nov 2006, Newhouse 4 Key ADME questions Carlson and Segall, Curr.Drug Disc (2002) Drugability Attrition Appropriate PK Target affinity vs ADME

PhysChem Forum, 29 Nov 2006, Newhouse 5 ADMET screening strategy Biopharmaceutical (physchem) profiling Pharmacokinetics Metabolism Early toxicology In vitro = wet screening In silico = web screening In combo In cerebro

PhysChem Forum, 29 Nov 2006, Newhouse 6 Wet screening (in vitro measurement)

PhysChem Forum, 29 Nov 2006, Newhouse 7 Han very early days Leiden (PhD) log P vs log k Are rate constants of partitioning useful in QSAR?

PhysChem Forum, 29 Nov 2006, Newhouse 8 Han early days Lausanne ( post-doc with Bernard Testa) pKa - Apple III, IBM PC log k HPLC - first attempts to HT log P = aV +  = hydrophobicity + polarity = size + hydrogen bonding

PhysChem Forum, 29 Nov 2006, Newhouse 9 Han early days Roche (Molecular Properties Group) pKa (GLpKa101, John Comer, Colin Peake) log k HPLC log P app (artificial membranes pre-PAMPA, Gian Camenisch) PAMPA (Manfred Kansy) PSA – polar surface area Van de Waterbeemd and Kansy, Chimia 46 (1992)

PhysChem Forum, 29 Nov 2006, Newhouse 10 Han more recent days Pfizer ( automated ADME screening) log D - 96 well plates log S PAMPA Pfizer (in silico ADME)

PhysChem Forum, 29 Nov 2006, Newhouse 11 Lessons learned Calculation goes faster Computed data often good enough No need to measure too much In silico for virtual compounds But, good quality experimental data are needed to build robust models

PhysChem Forum, 29 Nov 2006, Newhouse 12 Kinetic vs equilibrium Water Membrane Water Caco-2 PAMPA (cm/s) log P log D log k (w/o) = a log P + b log (  P+1) + c Kubinyi, 1978 Van de Waterbeemd et al, 1981

PhysChem Forum, 29 Nov 2006, Newhouse 13 Permeability = lipophilicity scale Lipophilicity (log P/D) Absorption log D oct log D dodecane PAMPA Caco-2 In reality sigmoidal relationships Permeability?

PhysChem Forum, 29 Nov 2006, Newhouse 14 Web screening (in silico prediction)

PhysChem Forum, 29 Nov 2006, Newhouse 15 Why in silico ? Lots of compounds (libraries, parallel synthesis) Lots of data (in vitro ADME/physchem screening) Screening is expensive In vitro models not always predictive for in vivo (e.g. Caco-2, PAMPA) In silico models to complement and/or replace in vitro/in vivo Only option for virtual compounds Guide in decision-making

PhysChem Forum, 29 Nov 2006, Newhouse 16 In silico Sound QSAR and molecular modeling methods/tools are available Commercial and in-house solutions for physchem and ADME screening data Modeling and simulation for human PK Confidence is growing

PhysChem Forum, 29 Nov 2006, Newhouse 17  Artificial GI fluid and buffered water are models for solubility in human GI  In silico models of these surrogate conditions are therefore a model of a model  What is predictive power of such solubility models?  We don’t take solid state properties into account! Human GI Artificial GI Aqueous buffer r 2 = 0.7r 2 = 0.7 r 2 =0.5 In silico solubility ?

PhysChem Forum, 29 Nov 2006, Newhouse 18 In silico PAMPA and Caco-2 ?  Caco-2 and PAMPA are models for oral absorption  In silico models of Caco-2 and PAMPA are therefore a model of a model  What is predictive power of such models? in vivo in vitro in silico Human %ACaco-2/PAMPACaco-2/PAMPA models r 2 = 0.7r 2 = 0.7 r 2 =0.5 model x model = random

PhysChem Forum, 29 Nov 2006, Newhouse 19 C. Lupfert, A. Reichel, Chem.Biodivers. 2 (2005) good uncertain poor

PhysChem Forum, 29 Nov 2006, Newhouse 20 Unravelling the processes Bioavailability Liver first-pass metabolism Absorption Transporters Gut-wall metabolism Permeability Lipophilicity Molecular size Molecular shape Flexibility Hydrogen bonding Solubility In vitro and in silico screens? ADME

PhysChem Forum, 29 Nov 2006, Newhouse 21 Design Clinical Candidate Lead Optimization Development Lead Profiling A% human measured = % !! R-o-5 MW<500 ClogP<5 HBA<10 HBD<5 >60% Single Descriptors MW<500 0<ClogP<4 0<logD<3 PSA<140A % QSAR Structural Descriptors 75% ACAT PBPK ppb pKa logD Caco-2 PAMPA P eff Vmax, Km Solubility 78% Population % Prediction of A%

PhysChem Forum, 29 Nov 2006, Newhouse 22 Towards prediction paradise? Solubility A% F% log D CLVd T 1/2 IC 50 Dose Tox Van de Waterbeemd and Gifford, Nature Revs. Drug Disc. 2 (2003) ADME Activity Toxicity

PhysChem Forum, 29 Nov 2006, Newhouse 23 Future developments Property-based design is best practise In combo approach established in drug discovery Further progress in silico QSAR technology New ADME/T world Pharma industry fully adapts in silico approach to design, screening, and optimisation

PhysChem Forum, 29 Nov 2006, Newhouse 24 In vitro + in silico = in combo Yu and Adedoyin, Drug Disc.Today 8, (2003) Dickins and Van de Waterbeemd, DDT: Biosilico, 2, (2004) Integration of experimental and computational technologies - Reducing cost of screening - Maximising data information

PhysChem Forum, 29 Nov 2006, Newhouse 25 ADME technologies - autoQSAR Automated model building and updating DataBuild in silico model Update in silico model J.Cartmell et al, J.Comp.-Aid.Mol.Des. 19 (2005) in combo in vitro priorities

PhysChem Forum, 29 Nov 2006, Newhouse 26 In vitro: logP conferences Great series of meetings, Excellent Proceedings Lausanne 1995, 2000 Zurich 2004, 2009

PhysChem Forum, 29 Nov 2006, Newhouse 27 QSAR has its attraction … In silico: EuroQSAR conferences

PhysChem Forum, 29 Nov 2006, Newhouse 28 References Volume 5 ADME-Tox Approaches (B. Testa and H. van de Waterbeemd), Elsevier, November 2006

PhysChem Forum, 29 Nov 2006, Newhouse 29 Thanks et bon appetit……

PhysChem Forum, 29 Nov 2006, Newhouse 30